Europe Castrate-resistant Prostate Cancer Market Size & Outlook

The castrate-resistant prostate cancer market in Europe is expected to reach a projected revenue of US$ 4,817.5 million by 2027. A compound annual growth rate of 8.4% is expected of Europe castrate-resistant prostate cancer market from 2019 to 2027.
Revenue, 2018 (US$M)
$2,325.4
Forecast, 2027 (US$M)
$4,817.5
CAGR, 2019 - 2027
8.4%
Report Coverage
Europe

Europe castrate-resistant prostate cancer market highlights

  • The Europe castrate-resistant prostate cancer market generated a revenue of USD 2,325.4 million in 2018.
  • The market is expected to grow at a CAGR of 8.4% from 2019 to 2027.
  • In terms of segment, hormonal therapy was the largest revenue generating therapy in 2018.
  • Immunotherapy is the most lucrative therapy segment registering the fastest growth during the forecast period.
  • Country-wise, UK is expected to register the highest CAGR from 2019 to 2027.


Europe data book summary

Market revenue in 2018USD 2,325.4 million
Market revenue in 2027USD 4,817.5 million
Growth rate8.4% (CAGR from 2018 to 2027)
Largest segmentHormonal therapy
Fastest growing segmentImmunotherapy
Historical data covered2016 - 2017
Base year for estimation2018
Forecast period covered2019 - 2027
Quantitative unitsRevenue in USD million
Market segmentationChemotherapy, Hormonal Therapy, Immunotherapy, Radiotherapy
Key market players worldwideSanofi SA, Johnson & Johnson, Pfizer Inc, Astellas Pharma Inc, Bayer AG


Other key industry trends

  • In terms of revenue, Europe region accounted for 28.6% of the global castrate-resistant prostate cancer market in 2018.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2027.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 3,004.5 million by 2027.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Castrate-resistant Prostate Cancer Market Scope

Castrate-resistant Prostate Cancer Market Companies

Name Profile # Employees HQ Website

Europe castrate-resistant prostate cancer market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to castrate-resistant prostate cancer market will help companies and investors design strategic landscapes.


Hormonal therapy was the largest segment with a revenue share of 82.8% in 2018. Horizon Databook has segmented the Europe castrate-resistant prostate cancer market based on chemotherapy, hormonal therapy, immunotherapy, radiotherapy covering the revenue growth of each sub-segment from 2016 to 2027.


Reasons to subscribe to Europe castrate-resistant prostate cancer market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Europe castrate-resistant prostate cancer market databook

  • Our clientele includes a mix of castrate-resistant prostate cancer market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Europe castrate-resistant prostate cancer market, including forecasts for subscribers. This continent databook contains high-level insights into Europe castrate-resistant prostate cancer market from 2016 to 2027, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Europe castrate resistant prostate cancer market size, by country, 2016-2027 (US$M)

Europe Castrate-resistant Prostate Cancer Market Share, 2018 & 2027 (US$M)

Europe castrate resistant prostate cancer market size, by country, 2016-2027 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more